<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00920166</url>
  </required_header>
  <id_info>
    <org_study_id>PET-CL3-001</org_study_id>
    <nct_id>NCT00920166</nct_id>
  </id_info>
  <brief_title>Evaluation of Safety, Growth, Tolerance and Effects on the Intestinal Fora of a New Milk for Healthy Infants</brief_title>
  <acronym>Pétunia</acronym>
  <official_title>Growth and Tolerance in New Born Fed Formula Supplemented With Alpha-Lactalbumin and Containing a Symbiotic</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sodilac</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sodilac</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess growth and tolerance in new born and infant fed an&#xD;
      experimental infant formula with reduced total protein concentration, enriched in&#xD;
      alpha-lactalbumin and containing a symbiotic.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective, randomized, double blind, controlled study evaluated the safety and effect&#xD;
      on growth and tolerance to an infant formula supplemented with alpha-lactalbumin and&#xD;
      containing a symbiotic, in term infants.&#xD;
&#xD;
      Term infants with a gestational age ranging from 37 to 42 weeks and whose parents chose&#xD;
      formula feeding were enrolled during their first eight days of life.&#xD;
&#xD;
      Both parents provided informed written consent. Infants were randomly assigned to receive&#xD;
      either the new test formula or a control, a regular formula adapted for term infants&#xD;
      (Modilac®1). The control formula is formulated to meet the nutritional needs of infants.&#xD;
&#xD;
      For each neonates, neonatal parameters were collected.&#xD;
&#xD;
      5 visits took place : V1 (inclusion), V2 (randomization), V3 (1 month), V4 (3 months) and V5&#xD;
      (6 months). During each visit, the investigator filled in observational book the&#xD;
      anthropometric parameters (weight, height, head circumference, BMI) and pieces of information&#xD;
      collected 3 days before by the parents (gastrointestinal tolerance parameters, daily infant&#xD;
      behaviour and milk consumption). Global parents' contentment was evaluated as well.&#xD;
&#xD;
      In two investigation centers, at the end of the 6th month, immuno-allergic test was realised.&#xD;
&#xD;
      Stools were collected at the end of the first and sixth month from diapers, for&#xD;
      microbiological analysis and measurements of faecal inflammatory markers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Growth Parameters</measure>
    <time_frame>1, 3 and 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sensitization or allergy</measure>
    <time_frame>1, 3 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atopic diseases (eczema atopic, asthma, allergic rhinitis)</measure>
    <time_frame>1, 3 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Describe the intestinal flora according to the nutrition group</measure>
    <time_frame>1 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Tolerance</measure>
    <time_frame>1 and 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">97</enrollment>
  <condition>Growth</condition>
  <arm_group>
    <arm_group_label>Modilac Pétunia 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Formula with reduced total protein concentration, enriched in alpha-lactalbumin and containing a symbiotic</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Modilac 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Regular milk</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Pétunia 1</intervention_name>
    <description>Infant formula used for non breastfed children</description>
    <arm_group_label>Modilac Pétunia 1</arm_group_label>
    <other_name>Modilac Pétunia 1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Regular formula</intervention_name>
    <description>Infant formula used for non breastfed children</description>
    <arm_group_label>Modilac 1</arm_group_label>
    <other_name>Modilac 1</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Term health newborn infant with gestational age ranging from 37 to 42 weeks&#xD;
&#xD;
          -  Eutrophic&#xD;
&#xD;
          -  Non breastfed children&#xD;
&#xD;
          -  Apgar score &gt; 5 to 7 minutes&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Infant presenting a metabolic, nervous, digestive or organic disease able to interfere&#xD;
             with study&#xD;
&#xD;
          -  Evidence of protein cow milk allergy&#xD;
&#xD;
          -  Infant presenting lactose intolerance&#xD;
&#xD;
          -  Newborn whose parents did not provide informed consent&#xD;
&#xD;
          -  Newborn currently participating in another trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>8 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean Christophe Rozé, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Nantes</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU d'Angers</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Vincent de Paul (AP-HP)</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Pitié Salpétrière</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <study_first_submitted>June 12, 2009</study_first_submitted>
  <study_first_submitted_qc>June 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2009</study_first_posted>
  <last_update_submitted>June 12, 2009</last_update_submitted>
  <last_update_submitted_qc>June 12, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 15, 2009</last_update_posted>
  <responsible_party>
    <name_title>Pr Jean Christophe Rozé (Principal investigator)</name_title>
    <organization>CHU de Nantes</organization>
  </responsible_party>
  <keyword>Infant formula</keyword>
  <keyword>Alpha-lactalbumin</keyword>
  <keyword>Symbiotic</keyword>
  <keyword>Allergy</keyword>
  <keyword>Gastrointestinal tolerance</keyword>
  <keyword>Bacterial colonization</keyword>
  <keyword>Faecal IgA analysis</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

